StemTherapy News.net

Stem cell therapy Xagena

Ataxia telangiectasia: a brain and spinal cancer following human fetal stem cell therapy


A case report published in the journal, PLoS Medicine, describes a rare side effect of human fetal stem cell therapy.
Ninette Amariglio and Gideon Rechavi from the Sheba Medical Center, Tel Aviv, Israel, and colleagues report the case of a boy with a rare genetic disease, ataxia telangiectasia, who underwent human fetal stem cell therapy at an unrelated clinic in Moscow and who, four years after the therapy began, was shown to have abnormal growths in his brain and spinal cord.

There have been reports in rodents of the development of tumors following the injection of pluripotential embryonic stem cells into recipient animals, although the risk of such tumors can be reduced if the cells are differentiated before being injected. However, this report is the first documented example of such a complication in a human following neural fetal stem cell therapy.

The spinal cord growth was surgically removed and this was shown to resemble a glioneuronal tumor, a type of benign neural tumor. The Authors describe the process by which they analyzed the tumor and documented that it could not have arisen from the patient's own tissues. For example, the tumor contained both XX ( female ) and XY ( male ) cells and had two normal copies of the ATM gene ( the gene causing ataxia telangiectasia, which was mutated in the patient ).

The researchers speculate that the patient's underlying condition may itself have allowed the tumor to become established, since individuals with ataxia telangiectasia often have an impaired immune system.
Although this report indicates the need for caution in stem cell therapy, the researchers have concluded that their findings do not imply that the research in stem cell therapeutics should be abandoned. They do, however, suggest that extensive research into the biology of stem cells and in-depth preclinical studies, especially of safety, should be pursued in order to maximize the potential benefits of regenerative medicine while minimizing the risks.

Source: Public Library of Science, 2009

XagenaMedicine_2009



Indietro